Flotetuzumab

N/A

Report date: 2026/03/19 16:46:23

Base Information

Drug NameFlotetuzumab
Drug Alias NameCD123-x-CD3S-80880MGD-006RES-234
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionInterleukin-3 receptor subunit alpha inhibitorsCD3 T-cell engagers
TargetsT cell surface glycoprotein CD3Interleukin-3 receptor subunit alpha
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmHematologic NeoplasmsNeoplasms, Plasma Cell +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsItaly +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLaboratoires ServierNational Cancer Institute
Inactive CompaniesWashington University School Of MedicineMacrogenics Inc
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmHematologic NeoplasmsNeoplasms, Plasma Cell +[12] 
Inactive IndicationsLeukemia, Biphenotypic, Acute

Other Information

ATC CodeN/A
Related LinksN/A